Esoteric Testing Market worth $48.3 billion by 2029

Prominent players in the market include Quest Diagnostics (US), Labcorp (US), H.U. Group Holdings, Inc. (Japan), Sonic Healthcare (Australia), OPKO Health, Inc. (US), Myriad Genetics, Inc. (US), The Mayo Foundation for Medical Education and Research (MFMER) (US)
The global esoteric testing market [https://www.marketsandmarkets.com/Market-Reports/esoteric-testing-market-76794708.html], valued at US$29.9 billion in 2023, is forecasted to grow at a robust CAGR of 8.5%, reaching US$32.2 billion in 2024 and an impressive US$48.3 billion by 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics. Growth in the market is primarily driven by the growing geriatric population, advancements in esoteric tests for personalized medicine, increasing research funding for precision medicine, and increase in drug and alcohol abuse and stringent laws mandating drug and alcohol testing.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76794708 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76794708&utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]

Browse in-depth TOC on "Esoteric Testing Market"

273 - Tables

48 - Figures

304 - Pages

The oncology testing segment is projected to register the highest CAGR in the forecasted period for esoteric testing market, by type segment, in 2023

Based on type, the esoteric testing market is segmented as infectious disease testing, autoimmune disease testing, endocrinology testing, oncology testing, genetic testing, toxicology and drug monitoring testing, neurology testing, and other types of testing. Esoteric oncology tests are used to determine the hereditary risk of cancer and are essential in diagnosis, prognosis, and treatment decisions. The growth of the oncology testing segment is driven by the rising prevalence of cancer and the increased adoption of various esoteric tests. The rising geriatric population is one of the major factors resulting in the increasing incidence of cancer.

In 2023, the enzyme-linked immunosorbent assay (ELISA) segment held the largest share of the esoteric testing market, by technology segment.

Based on technology, the esoteric testing market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), real-time PCR, chromatography and mass spectrometry, flow cytometry, DNA sequencing and next-generation sequencing, and other technologies. The ELISA, or Enzyme-Linked Immunosorbent Assay, is a widely used biochemical technique for detecting the presence of an antigen (such as a protein) or an antibody in a sample. It relies on the principle of antigen-antibody interactions and utilizes enzymes to generate a measurable signal. The large share of the ELISA segment is attributed to the advantages of ELISA over other testing methods, such as high efficiency, as simultaneous analyses can be performed without complicated sample pre-treatment, high specificity and sensitivity because of an antigen-antibody reaction, cost-effectiveness, as low-cost reagents are used, and safe and eco-friendly nature.

The blood, serum, and plasma segment accounted for largest market share of esoteric testing market, by specimen, in 2023

Based on specimens, the esoteric testing market is segmented into blood, serum, and plasma, urine, and other specimens. The blood, serum, and plasma segment accounted for the largest share of the esoteric testing market in 2023. The large share of the blood, serum, and plasma segment can be attributed to the rising prevalence of chronic and infectious diseases and the increasing number of blood donations globally.

The independent & reference laboratories segment accounted for the largest share of the esoteric testing market, by end user, in 2023

Based on end users, the esoteric testing market is segmented into independent & reference laboratories and hospital-based laboratories. The independent & reference laboratories segment accounted for the largest share of the esoteric testing market, as of 2023. The large share of this segment is attributed to the preference of highly accurate and reliable diagnostic tests, improved insurance coverage for complex diagnostic tests, and digitalization of diagnostic laboratories across major countries.

The Asia Pacific market is expected to witness the highest growth during the forecast period.

The global esoteric testing market is divided into six key regions: North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR of 10.1% in the esoteric testing market during the forecast period. The presence of emerging economies such as China, India, and Japan, the rising prevalence of chronic diseases, improving standard of living, growing demand for quality medical care, increasing healthcare spending, favorable government initiatives, and growing awareness regarding the use of esoteric tests among physicians are some of the major factors driving the growth of the esoteric testing market in the Asia Pacific.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76794708 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=76794708&utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]

Key Market Players of Esoteric Testing Industry:

Prominent players in the market include Quest Diagnostics (US), Labcorp (US), H.U. Group Holdings, Inc. (Japan), Sonic Healthcare (Australia), OPKO Health, Inc. (US), Myriad Genetics, Inc. (US), The Mayo Foundation for Medical Education and Research (MFMER) (US), Eurofins Scientific (Luxembourg), Stanford Health Care (US), Foundation Medicine, Inc. (US), Kindstar Globalgene Technology, Inc. (China), Georgia Esoteric & Molecular Laboratory, LLC (US), Thyrocare Technologies Ltd. (India), ACM Global Laboratories (US), NMS Labs (US), HealthQuest Esoterics (US), Cerba Research (US), LeoLabs (India), Flow Health (US), Invitae Corporation (US), ARUP Laboratories (US), Fulgent Genetics (US), bioMONTR Labs (US), and LabGenomics (South Korea).

The primary interviews conducted for this report can be categorized as follows:

* By Company Type: Tier 1 - 45%, Tier 2 - 38%, and Tier 3 - 17%
* By Designation: C-level - 24%, D-level - 32%, and Others - 44%
* By Region: North America - 35%, Europe - 26%, Asia Pacific - 24%, Latin America - 12%, Middle East & Africa - 1%, and the GCC Countries - 2%

Recent Developments of Esoteric Testing Industry:

* In April 2024, Labcorp launched glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.
* In April 2024, Quest launched a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is useful for the early diagnosis of AD.
* In March 2024, Labcorp launched pTau217 test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the diagnosis of Alzheimer's disease and the subsequent monitoring of patients undergoing treatment with new Alzheimer's disease therapies.

Esoteric Testing Market - Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall esoteric testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, trends, and opportunities.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=76794708 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=76794708&utm_source=Prnewswire&utm_medium=referral&utm_campaign=paidpr]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esoteric-testing-market-worth-483-billion-by-2029]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/esoteric-testing-market-76794708.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.